The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.

2023-04-03
Active
Early
S21
17
Healthcare
United KingdomSlovakiaEuropeRemotePartly Remote
Sensible Biotechnologies screenshot
Sensible Biotechnologies рдХреЗ рдмрд╛рд░реЗ рдореЗрдВ рдЕрдзрд┐рдХ рдЬрд╛рдирдХрд╛рд░реА

Sensible Biotechnologies: mRNA. Made Better.

Introduction

Sensible Biotechnologies is revolutionizing the future of mRNA therapeutics and vaccines by leveraging engineered living cells to produce high-quality, stable, and non-immunogenic mRNA in a scalable and cost-effective manner.

Key Features

  • Cell-Based mRNA Production: Utilizing engineered living cells for efficient and scalable mRNA manufacturing.
  • High-Quality mRNA: Producing abundant, highly stable, and non-immunogenic mRNA.
  • Cost-Effective Manufacturing: Reducing costs to improve access to mRNA technology.
  • Scalable Production: Enhancing biosecurity and supply chain resilience.
  • Innovative Platform: Combining cell engineering, computational biology, and precision fermentation.

Use Cases

  • mRNA Vaccines: Developing next-generation vaccines with improved efficacy and stability.
  • Therapeutics: Creating novel mRNA-based treatments for various diseases.
  • Biosecurity: Strengthening supply chain resilience and biosecurity through scalable production methods.
  • Research and Development: Supporting academic and industrial research with high-quality mRNA.

Pricing

Sensible Biotechnologies offers competitive pricing models tailored to the needs of different clients, ensuring cost-effective access to cutting-edge mRNA technology. Contact us for detailed pricing information and custom solutions.

Teams

Our team comprises leading experts in mRNA manufacturing, synthetic biology, and life sciences, including:

  • Miroslav Gasparek: Co-Founder and Chief Executive Officer
  • Marian Kupculak, DPhil: Co-Founder and Chief Scientific Officer
  • Paul Sobotka, MD: Vice President of Clinical Research
  • Anton McCaffrey, PhD: Vice President of Manufacturing Strategy
  • Leanne Minall, DPhil: Head of Science
  • Michal Karlubik: Head of Partnerships & External Affairs
  • Akos Melecske, MA: Head of Finance and Operations
  • Krishna Motheramgari, PhD: Principal Computational Scientist
  • Robert Hieronymus, PhD: Senior Scientist
  • Kelvin Yaprianto, DPhil: Senior Scientist
  • Liudmyla Kapustian, PhD: Senior Scientist
  • Martina Belkova, PhD: Scientist
  • Smruti Rashmi, PhD: Scientist
  • Neelam Mehta: Scientist and Lab Manager
  • Emily Buck: Scientist
  • Mario Simo Hernando: Associate Scientist
  • Alexandra Vargova: Associate Computational Scientist
  • Romana Halova: Scientist
  • Dominika Valachova: Associate Scientist
  • Vikram Shaw: Research Scientist
  • Kazimir Uzwyshyn-Jones: Research Scientist
  • Alexandra Korobova: Executive Assistant
  • Kristina Balcokova: Associate Scientist

Join our team of experts and contribute to the future of mRNA technology. We are hiring cell engineers, bioprocess engineers, mRNA Quality Control analysts, and RNA computational biologists for our Oxford site. Contact us to learn more about career opportunities.

Sensible Biotechnologies рдХреЗ рд╡рд┐рдХрд▓реНрдк

ParcelBio logo

ParcelBio

рдЕрдЧрд▓реА рдкреАрдврд╝реА рдХреА mRNA рджрд╡рд╛рдПрдВ

Engage Bio logo

Engage Bio

рдХреИрдВрд╕рд░ рдХреЛ рдЦрддреНрдо рдХрд░рдиреЗ рдХреЗ рд▓рд┐рдП mRNA рдЗрдореНрдпреВрдиреЛрдереЗрд░реЗрдкреА

Cisterna Biologics logo

Cisterna Biologics

рдЪрд┐рдХрд┐рддреНрд╕реАрдп рдЕрдиреБрдкреНрд░рдпреЛрдЧреЛрдВ рдХреЗ рд▓рд┐рдП рдЙрдЪреНрдЪ рдЧреБрдгрд╡рддреНрддрд╛ рд╡рд╛рд▓рд╛ mRNA

Kernal Biologics logo

Kernal Biologics

рдХреЗрд░реНрдирд▓ mRNA 2.0 рдереЗрд░реЗрдкреА рдмрдирд╛ рд░рд╣рд╛ рд╣реИ рдЬреЛ рд╡рд┐рд╢рд┐рд╖реНрдЯ рдХреЛрд╢рд┐рдХрд╛рдУрдВ рдореЗрдВ рдХрд╛рдо рдХрд░рддреА рд╣реИ

Serna Bio logo

Serna Bio

рдореИрдкрд┐рдВрдЧ рдж рдбреНрд░рдЧрдПрдмрд▓ рдЯреНрд░рд╛рдВрд╕рдХреНрд░рд┐рдкреНрдЯреЛрдо

Helix Nanotechnologies logo

Helix Nanotechnologies

рдХреИрдВрд╕рд░, COVID рдФрд░ рдЬрд▓рд╡рд╛рдпреБ рдХреЛ рд╣рд▓ рдХрд░рдиреЗ рдХреЗ рд▓рд┐рдП рдЕрдЧрд▓реА рдкреАрдврд╝реА рдХрд╛ mRNA рдкреНрд▓реЗрдЯрдлреЙрд░реНрдоред

GEn1E Lifesciences logo

GEn1E Lifesciences

рджреБрд░реНрд▓рдн рдФрд░ рд╕реВрдЬрди рд╕рдВрдмрдВрдзреА рдмреАрдорд╛рд░рд┐рдпреЛрдВ рдХреЗ рд▓рд┐рдП рдЙрдкрдЪрд╛рд░реЛрдВ рдХреЛ рддреЗрдЬ рдХрд░рдиреЗ рд╡рд╛рд▓рд╛ AI рдкреНрд▓реЗрдЯрдлрд╝реЙрд░реНрдоред

рд╕рд╛рдкреНрддрд╛рд╣рд┐рдХ рд╢реАрд░реНрд╖ 10 рдЙрддреНрдкрд╛рдж